Skip to main content
. 2020 Dec 8;15(5):396–405. doi: 10.1097/ADM.0000000000000778

TABLE 3.

Copositivity Analysis – Methamphetamine Positive Versus Negative Population Odds Ratios

Region/Year Benzodiazepines Buprenorphine Cocaine Alcohol Fentanyl Heroin Methadone Opioids THC
US Total
 2014 1.86 (1.49–2.33) 1.7 (1.34–2.16) 2.44 (1.97–3.03) 1.38 (1.09–1.74) 1.11 (0.67–1.84) 4.38 (3.25–5.91) 2.23 (1.49–3.35) 2.59 (2.13–3.14) 2.65 (2.21–3.19)
 2015 1.83 (1.61–2.08) 1.64 (1.39–1.94) 1.93 (1.66–2.25) 1.01 (0.84–1.22) 1.69 (1.33–2.13) 4.2 (3.5–5.05) 1.65 (1.11–2.45) 2.8 (2.49–3.16) 2.47 (2.18–2.8)
 2016 2.01 (1.77–2.28) 1.56 (1.31–1.85) 2.21 (1.91–2.56) 1.11 (0.93–1.33) 2.15 (1.71–2.69) 5.38 (4.42–6.56) 1.78 (1.34–2.35) 2.95 (2.58–3.38) 2.44 (2.15–2.78)
 2017 1.79 (1.55–2.07) 1.92 (1.62–2.26) 2.26 (1.94–2.64) 1.1 (0.94–1.29) 2.95 (2.43–3.57) 5.41 (4.18–7.01) 2.19 (1.62–2.97) 2.59 (2.23–3) 2.74 (2.41–3.12)
 2018 1.87 (1.64–2.14) 2.01 (1.68–2.39) 2.54 (2.17–2.97) 1.04 (0.88–1.23) 4.05 (3.36–4.88) 7.5 (5.75–9.78) 1.6 (1.02–2.51) 3.41 (2.96–3.92) 2.82 (2.5–3.19)
 2019 1.6 (1.38–1.85) 2.01 (1.71–2.37) 2.43 (2.1–2.81) 1.09 (0.95–1.26) 4.35 (3.73–5.08) 8.09 (6.31–10.36) 1.8 (1.24–2.6) 3.41 (2.98–3.89) 2.62 (2.34–2.93)
East North Central
 2014 1.88 (1.19–2.98) 2.33 (1.26–4.34) 2.18 (1.23–3.85) 1.04 (0.54–2.01) 1.9 (0.57–6.32) 3.83 (2.08–7.06) 3.24 (1.55–6.77) 3.54 (2.21–5.65) 2.48 (1.65–3.71)
 2015 2.06 (1.52–2.8) 1.92 (1.33–2.78) 2.48 (1.78–3.45) 0.83 (0.53–1.3) 3.56 (2.3–5.49) 3.13 (2.19–4.47) 1.67 (0.8–3.5) 3.64 (2.71–4.89) 2.25 (1.68–3)
 2016 1.99 (1.48–2.66) 1.92 (1.39–2.66) 2.93 (2.18–3.94) 0.9 (0.61–1.31) 3.9 (2.83–5.36) 3.48 (2.49–4.88) 0.9 (0.42–1.91) 3.4 (2.6–4.44) 2.18 (1.67–2.84)
 2017 1.81 (1.3–2.51) 2.31 (1.64–3.24) 2.81 (2.03–3.89) 0.92 (0.62–1.38) 4.99 (3.56–7.01) 4.14 (2.69–6.38) 1.92 (0.9–4.08) 3.05 (2.28–4.09) 2.36 (1.81–3.07)
 2018 1.66 (1.27–2.17) 2.06 (1.59–2.68) 2.62 (2.06–3.35) 0.92 (0.68–1.25) 5.38 (4.23–6.83) 4.76 (3.31–6.85) 0.97 (0.45–2.08) 3.4 (2.72–4.25) 2.22 (1.81–2.72)
 2019 1.72 (1.37–2.14) 1.75 (1.39–2.21) 2.15 (1.76–2.62) 0.82 (0.64–1.06) 4.35 (3.64–5.21) 4.57 (3.34–6.24) 1.67 (1.22–2.3) 3.53 (2.94–4.24) 2.12 (1.8–2.5)
East South Central
 2014 2.86 (2.07–3.95) 2.69 (1.71–4.22) 2.19 (1.3–3.67) 1.34 (0.76–2.34) 1.79 (0.53–6) 3.14 (1.11–8.92) 2.79 (1.46–5.36) 2.15 (1.53–3.03) 2.74 (2.01–3.74)
 2015 2.45 (1.93–3.11) 1.98 (1.43–2.73) 1.78 (1.22–2.6) 1.32 (0.93–1.87) 1.91 (0.98–3.72) 4.07 (2.44–6.8) 2.35 (1.41–3.91) 2.4 (1.88–3.07) 3.19 (2.55–3.99)
 2016 2.31 (1.82–2.92) 1.65 (1.2–2.27) 1.89 (1.33–2.7) 1.24 (0.91–1.68) 3.69 (2.42–5.64) 5.38 (3.39–8.52) 2.29 (1.15–4.57) 2.39 (1.89–3.01) 2.88 (2.32–3.58)
 2017 2.16 (1.74–2.7) 2.04 (1.51–2.77) 1.99 (1.46–2.71) 1.25 (0.94–1.67) 4.8 (3.52–6.56) 5.85 (3.76–9.1) 1.46 (0.7–3.05) 2.8 (2.26–3.47) 3.46 (2.84–4.22)
 2018 1.83 (1.47–2.29) 1.91 (1.45–2.53) 1.81 (1.35–2.43) 1.02 (0.79–1.33) 4.71 (3.68–6.04) 5.51 (3.69–8.24) 1.25 (0.56–2.77) 3.27 (2.67–4.01) 3.41 (2.84–4.1)
 2019 1.62 (1.26–2.09) 1.84 (1.42–2.4) 1.68 (1.23–2.29) 0.99 (0.75–1.29) 3.94 (3.13–4.96) 4.63 (3.05–7.01) 1.12 (0.6–2.09) 2.85 (2.3–3.55) 2.79 (2.3–3.39)
Mid Atlantic
 2014 2.74 (1.57–4.76) 2.45 (1.27–4.76) 2.63 (1.43–4.81) 1.5 (0.62–3.63) 0.92 (0.1–8.31) 2.89 (1.38–6.05) 1.73 (0.7–4.27) 2.49 (1.4–4.43) 2.49 (1.35–4.59)
 2015 2.14 (1.21–3.78) 2.66 (1.26–5.6) 2.37 (1.26–4.47) 0.56 (0.17–1.83) 2.98 (1–8.86) 4.15 (2.04–8.44) 1.57 (0.58–4.24) 3.81 (2.21–6.57) 2.14 (1.13–4.06)
 2016 2.6 (1.44–4.7) 2.09 (0.93–4.67) 3.01 (1.54–5.86) 1.12 (0.5–2.51) 6.16 (2.91–13.02) 6.36 (3–13.49) 1.58 (0.38–6.54) 3.91 (2.06–7.44) 2.03 (1.08–3.78)
 2017 2.19 (0.94–5.06) 3.01 (1.2–7.57) 2.94 (1.24–6.98) 0.83 (0.28–2.49) 4.92 (1.7–14.27) 7.57 (2.48–23.08) 2.24 (0.41–12.34) 2.01 (0.86–4.66) 2.21 (1.06–4.61)
 2018 3 (1.32–6.83) 5.64 (2.29–13.92) 3.07 (1.23–7.64) 0.8 (0.28–2.33) 6.38 (2.39–17.07) 7.71 (1.95–30.45) 2.03 (0.22–18.99) 3.34 (1.45–7.71) 2.38 (1.15–4.94)
 2019 1.92 (0.83–4.43) 6.04 (2.69–13.6) 2.87 (1.27–6.49) 1.14 (0.49–2.69) 6.17 (2.47–15.38) 4.78 (1.04–21.91) 2 (0.21–18.92) 2.12 (0.91–4.95) 1.8 (0.95–3.42)
Mountain
 2014 1.43 (1.15–1.79) 1.29 (0.77–2.16) 2.87 (1.97–4.19) 1.39 (1.07–1.79) 0.55 (0.15–1.97) 7.8 (5.32–11.44) 2.23 (1.43–3.47) 2.04 (1.61–2.58) 2.35 (1.91–2.88)
 2015 1.51 (1.22–1.86) 1.61 (1.04–2.49) 2.13 (1.44–3.17) 1.24 (0.98–1.58) 0.61 (0.21–1.74) 11.85 (8.64–16.26) 2.44 (1.58–3.76) 2.73 (2.21–3.38) 2.21 (1.83–2.68)
 2016 1.79 (1.35–2.35) 1.74 (1.05–2.9) 2.63 (1.72–4.03) 1.29 (0.97–1.73) 0.55 (0.15–2) 10.67 (7.32–15.56) 3.25 (2.19–4.83) 3.12 (2.37–4.12) 2.42 (1.93–3.04)
 2017 1.63 (1.2–2.22) 1.88 (1.12–3.18) 2.88 (1.84–4.5) 1.38 (1.01–1.88) 1.3 (0.53–3.16) 12.7 (8.47–19.04) 5.72 (3.32–9.87) 3.66 (2.75–4.85) 2.23 (1.75–2.85)
 2018 1.79 (1.31–2.44) 2.69 (1.63–4.43) 3.25 (2.01–5.26) 1.45 (1.08–1.94) 1.92 (0.93–3.96) 19.84 (12.96–30.37) 3.35 (1.93–5.8) 3.75 (2.86–4.92) 2.15 (1.69–2.73)
 2019 1.3 (0.99–1.71) 2.15 (1.49–3.12) 3 (2–4.5) 1.17 (0.92–1.51) 3.62 (2.5–5.25) 18.56 (12.28–28.07) 2.89 (1.76–4.73) 3.92 (3.15–4.88) 1.88 (1.54–2.3)
New England
 2014 0.83 (0.07–9.7) 3.3 (0.34–32.53) 4.64 (0.55–39.38) 1.92 (0.18–20.27) 1.45 (0.02–127.64) 4.94 (0.31–79.97) 1.49 (0.02–128.79) 3.04 (0.39–23.86) 1.89 (0.27–13.33)
 2015 1.27 (0.34–4.7) 1.09 (0.25–4.68) 2.47 (0.63–9.65) 0.62 (0.1–3.64) 6.64 (1.76–25.07) 3.33 (0.67–16.49) 0.49 (0.01–39.24) 2.59 (0.8–8.33) 1.53 (0.45–5.2)
 2016 2.87 (0.85–9.69) 1.38 (0.32–5.93) 3.5 (0.98–12.47) 0.77 (0.13–4.64) 9.75 (3.25–29.28) 6.8 (1.18–39.09) 1.58 (0.12–21.37) 3.21 (0.86–12.01) 1.73 (0.48–6.2)
 2017 2.05 (0.57–7.42) 2.18 (0.62–7.68) 3.07 (0.91–10.43) 0.84 (0.23–3.09) 9.15 (3.15–26.57) 2.81 (0.27–28.84) 1.36 (0.1–18.47) 1.88 (0.49–7.26) 3.14 (0.97–10.16)
 2018 2.54 (0.86–7.48) 2.24 (0.6–8.43) 4.56 (1.61–12.91) 0.58 (0.14–2.43) 11.21 (4.23–29.68) 3.76 (0.43–32.6) 0.43 (0.01–35.32) 3.73 (1.12–12.38) 3.12 (1.1–8.87)
 2019 1.8 (0.49–6.53) 2.65 (0.7–10.01) 3.23 (1.06–9.88) 0.83 (0.24–2.92) 8.57 (3.19–23) 10.81 (1.51–77.61) 1.02 (0.04–24.2) 6.16 (2.03–18.71) 2.64 (0.98–7.14)
Pacific
 2014 1.5 (1.25–1.8) 1.23 (0.86–1.76) 2.34 (1.65–3.32) 1.4 (1.15–1.71) 0.65 (0.26–1.66) 11.64 (8.55–15.86) 2.21 (1.54–3.17) 3.46 (2.9–4.13) 2.64 (2.24–3.11)
 2015 1.51 (1.29–1.78) 1.68 (1.28–2.22) 2.28 (1.69–3.07) 1.33 (1.12–1.57) 0.89 (0.42–1.9) 11.75 (8.92–15.48) 1.9 (1.32–2.73) 3.81 (3.27–4.44) 2.49 (2.17–2.86)
 2016 1.21 (1.01–1.46) 1.42 (1.06–1.9) 2.38 (1.77–3.2) 1.22 (1.03–1.44) 0.86 (0.44–1.69) 13.08 (10.06–17) 1.95 (1.33–2.85) 3.99 (3.4–4.68) 2.19 (1.91–2.5)
 2017 1 (0.83–1.22) 1.75 (1.37–2.24) 1.81 (1.35–2.44) 1.17 (1–1.38) 1.59 (0.97–2.62) 17.13 (12.87–22.8) 2.4 (1.65–3.49) 4.58 (3.93–5.34) 2.18 (1.93–2.48)
 2018 0.99 (0.81–1.22) 1.62 (1.27–2.08) 1.95 (1.42–2.67) 1.16 (0.99–1.37) 2.66 (1.74–4.08) 20.74 (16.05–26.81) 2.48 (1.72–3.58) 6.85 (5.87–8) 2.18 (1.92–2.48)
 2019 0.86 (0.68–1.08) 1.69 (1.33–2.15) 1.95 (1.38–2.76) 1.14 (0.97–1.35) 4.14 (2.76–6.22) 33.17 (24.38–45.13) 2.23 (1.42–3.49) 8.09 (6.83–9.57) 2.17 (1.9–2.48)
South Atlantic
 2014 2.11 (1.62–2.74) 1.43 (0.97–2.1) 2.33 (1.7–3.21) 1.2 (0.82–1.76) 1.2 (0.45–3.17) 2.8 (1.56–5) 2.52 (1.57–4.07) 2.74 (2.09–3.59) 2.5 (1.94–3.22)
 2015 1.92 (1.56–2.38) 1.28 (0.92–1.79) 1.61 (1.22–2.12) 1.07 (0.81–1.41) 1.38 (0.76–2.51) 1.81 (1.19–2.75) 1.67 (1.06–2.63) 2.27 (1.84–2.8) 2.56 (2.09–3.12)
 2016 1.86 (1.4–2.46) 1.36 (0.87–2.11) 2.11 (1.53–2.91) 1.03 (0.72–1.47) 1.92 (1.15–3.2) 2.58 (1.57–4.23) 1.55 (0.9–2.69) 2.45 (1.85–3.25) 2.31 (1.8–2.96)
 2017 1.61 (1.12–2.3) 1.86 (1.13–3.07) 1.75 (1.19–2.58) 0.92 (0.57–1.5) 1.96 (1.18–3.23) 2.42 (1.29–4.55) 1.85 (0.94–3.65) 2.13 (1.51–3.01) 2.33 (1.7–3.18)
 2018 1.43 (0.98–2.1) 1.22 (0.71–2.08) 2.45 (1.68–3.59) 1.2 (0.76–1.88) 2.55 (1.6–4.09) 4.72 (2.52–8.83) 1.78 (0.82–3.87) 2.37 (1.66–3.37) 2.73 (2–3.73)
 2019 1.62 (1.15–2.27) 1.33 (0.85–2.07) 2.55 (1.81–3.6) 1.05 (0.73–1.5) 3.36 (2.27–4.97) 5.84 (3.35–10.16) 1.76 (0.9–3.41) 2.32 (1.71–3.14) 2.56 (1.94–3.37)
West North Central
 2014 1.77 (1.22–2.57) 0.68 (0.28–1.63) 1.22 (0.55–2.69) 1.27 (0.82–1.97) 2.13 (0.53–8.58) 2.43 (0.71–8.32) 1.43 (0.66–3.11) 1.96 (1.32–2.91) 3.23 (2.34–4.47)
 2015 1.73 (1.38–2.18) 1.44 (0.83–2.49) 0.98 (0.6–1.6) 1.36 (1.06–1.75) 1.39 (0.54–3.55) 2.99 (1.81–4.93) 1.19 (0.69–2.05) 2.49 (1.96–3.16) 2.9 (2.38–3.54)
 2016 1.67 (1.35–2.06) 1.34 (0.82–2.19) 0.93 (0.61–1.41) 1.22 (0.98–1.53) 2.09 (1.3–3.37) 2.66 (1.74–4.07) 1.08 (0.64–1.82) 2.63 (2.11–3.28) 3.11 (2.61–3.7)
 2017 1.91 (1.43–2.55) 1.4 (0.82–2.41) 1.45 (0.81–2.62) 1.53 (1.14–2.04) 3.46 (1.95–6.16) 6.43 (2.89–14.31) 1.85 (0.81–4.23) 2.44 (1.79–3.35) 3.16 (2.52–3.97)
 2018 2.06 (1.43–2.96) 2.06 (1.15–3.66) 2.4 (1.17–4.9) 1.27 (0.86–1.86) 10.38 (5.35–20.13) 18.37 (6.46–52.22) 1.82 (0.62–5.37) 4.46 (3.01–6.61) 3.44 (2.62–4.52)
 2019 1.71 (1.21–2.41) 1.36 (0.76–2.41) 2.66 (1.56–4.54) 1.59 (1.15–2.19) 5.6 (3.44–9.11) 7.1 (3.42–14.75) 2.62 (1.1–6.25) 2.94 (2.04–4.24) 4.01 (3.12–5.15)
West South Central
 2014 2.74 (2.07–3.62) 1.54 (0.83–2.85) 2.79 (1.89–4.12) 1.52 (1.05–2.2) 0.6 (0.1–3.65) 5.59 (2.13–14.66) 3.32 (1.68–6.56) 2.38 (1.76–3.22) 4.11 (3.23–5.22)
 2015 2.22 (1.8–2.75) 1.58 (0.95–2.63) 1.91 (1.36–2.68) 1.22 (0.93–1.6) 0.78 (0.23–2.63) 3.09 (1.34–7.14) 3.3 (1.9–5.73) 2.1 (1.66–2.66) 3.57 (2.96–4.29)
 2016 2.29 (1.71–3.07) 1.32 (0.73–2.41) 1.73 (1.06–2.82) 1.37 (0.98–1.91) 0.59 (0.12–2.88) 4.89 (1.86–12.85) 3.23 (1.59–6.56) 2.07 (1.5–2.86) 3.68 (2.88–4.71)
 2017 2.16 (1.58–2.97) 1.3 (0.68–2.48) 2.32 (1.5–3.59) 1.3 (0.91–1.84) 1.12 (0.38–3.26) 2.28 (0.74–6.99) 2.91 (1.29–6.58) 1.86 (1.32–2.62) 4.29 (3.28–5.62)
 2018 2.34 (1.55–3.51) 0.97 (0.41–2.29) 1.77 (0.92–3.41) 1.24 (0.78–1.97) 1.18 (0.34–4.14) 2.75 (0.81–9.28) 2.36 (0.76–7.34) 1.64 (1.04–2.56) 4.61 (3.21–6.63)
 2019 2.34 (1.55–3.55) 1.6 (0.81–3.15) 2.2 (1.22–3.98) 1.3 (0.83–2.04) 2.2 (0.9–5.37) 5.3 (1.82–15.5) 1.73 (0.41–7.24) 2.18 (1.42–3.35) 4.88 (3.44–6.91)

A logistic regression model for each of the nine independent drug or drug classes was performed containing collection year, US census division, sex, age, health care specialty, methamphetamine detection status (positive or negative) main effects and collection year by US census division by methamphetamine detection status interaction effects. The drug or drug class detection was modeled as the response variable. Odds ratios (OR) were calculated for each model. OR estimates and 95% Sidak-corrected confidence intervals represent the odds of being positive for the response drug in the methamphetamine-positive population divided by the odds in the methamphetamine-negative population. Higher OR values represent higher copositivity values. OR was calculated for the Total US population and each individual US census division for each year of the study. Other opioids include codeine, hydrocodone, hydromorphone, morphine, oxycodone, and oxymorphone.

P < 0.05.

P < 0.01.

P < 0.001.